Teva reports 44-week duvakitug data for Teva stock

Teva Pharmaceutical Industries (ISIN US8816242098) and Sanofi reported 58 percent clinical remission for the 900 mg dose of duvakitug at Week 44 in ulcerative colitis. The October 20, 2026 update from Sanofi also showed 47 percent remission for the 450 mg dose.

Week 44 data sharpen the pipeline case

The result came from the RELIEVE UCCD phase 2b long-term extension study, which followed 130 responders through maintenance treatment. In Crohn's disease, endoscopic response reached 55 percent at 900 mg and 41 percent at 450 mg, according to Sanofi.

Duvakitug remains an investigational therapy, so the data support pipeline potential rather than commercial revenue. The dose comparison matters because clinical remission was 11 percentage points higher at 900 mg than at 450 mg in ulcerative colitis.

Three dated events frame the stock

On June 30, 2026, Teva reported USD 4.14 billion in quarterly revenue, according to MarketBeat. On October 12, 2026, Teva announced an R&D Day for November 11, with presentations starting at 8:30 a.m. Eastern Time, as GlobeNewswire reported. The October 20, 2026 duvakitug update was the latest of the three events.

What does November bring for Teva?

Teva's next two scheduled dates are its third-quarter 2026 results on November 3, 2026, and the R&D Day on November 11, 2026. The results date is listed by Simply Wall St, while the company event was announced through GlobeNewswire. Together, the dates put clinical durability, revenue execution and the wider pipeline on the same investor calendar.

Stock context before the next report

Teva was last at USD 39.95 on the NYSE on October 26, 2026 at 4:00 p.m. EDT. Its market capitalization was USD 46.6 billion, while its 52-week range was USD 19.00 to USD 42.02 on the same quote snapshot. The stock therefore remained below its yearly high as investors approached the November reporting date.

Market context: Market report S&P 500.

More news and analyses on Teva Pharmaceutical Industries stock